FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Alignment With Cognition Therapeutics On Vital Aspects To Support Its New Drug Application

Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate

Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 63.64 percent increase over losses of $(0.11) per

8-K filing — COGNITION THERAPEUTICS INC (CGTX)

Filed: 2026-06-24 AccNo: 0001104659-26-077060 Size: 218 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of Zervimesine